Skip to main content
An official website of the United States government

DCB Funding Opportunities

Funding Opportunity Announcements (FOA)

Title Announcement Number Opening Date Expiration Date Activity Code
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) RFA-CA-23-011 02/01/2023 09/02/2023 U2C
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) RFA-CA-23-010 02/01/2023 09/02/2023 P50
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) RFA-CA-23-009 02/01/2023 09/02/2023 P01
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) RFA-CA-23-008 02/01/2023 09/02/2023 U54
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) RFA-CA-23-007 02/01/2023 09/02/2023 U01
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) RFA-CA-23-006 02/01/2023 09/02/2023 R01
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-23-005 02/01/2023 09/02/2023 R33
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-23-004 02/01/2023 09/02/2023 R61
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) RFA-CA-23-003 02/01/2023 09/02/2023 R33
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) RFA-CA-23-002 02/01/2023 09/02/2023 R61
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-23-017 05/13/2023 11/18/2023 U24
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-23-016 05/13/2023 11/18/2023 U24
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) RFA-CA-23-015 05/13/2023 11/18/2023 U01
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) RFA-CA-23-014 05/13/2023 11/18/2023 R21
Notice of Special Interest (NOSI): Administrative supplements to conduct systematic evidence reviews on the clinical utility of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment NOT-CA-23-046 02/23/2023 04/22/2023 N/A
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology Research Programs NOT-CA-23-045 03/02/2023 04/21/2023 N/A
Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer NOT-CA-23-018 02/05/2023 09/08/2024 N/A
Request for Information on Existing Data Sharing Processes for NIH-Funded Research NOT-CA-23-023 02/02/2023 04/04/2023 N/A
Adaptive Biomaterials for Cancer Biology NOT-CA-23-030 01/10/2023 05/07/2025 N/A
MPS-NCI SuPporting new AReas of Knowledge (SPARK): Cancer as a Living Material – New Ideas and New Connection NSF 23-09 (NSF Dear Colleague Letter) 01/03/2023 03/11/2023 N/A
Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed) RFA-OD-22-008 05/30/2022 07/02/2024 R03
Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed) RFA-OD-22-009 05/30/2022 07/02/2024 R01
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) RFA-CA-22-056 11/15/2022 12/16/2023 R01
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) RFA-CA-22-057 11/15/2022 12/16/2023 R21
Biology of Bladder Cancer (R01 Clinical Trial Optional) PAR-22-218 09/05/2022 09/08/2025 R01
Biology of Bladder Cancer (R21 Clinical Trial Optional) PAR-22-219 09/16/2022 09/08/2025 R21
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) PAR-22-234 10/07/2022 06/21/2025 U01
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer NOT-CA-22-085 05/05/2022 05/08/2027 N/A
Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy NOT-CA-22-063 05/03/2022 07/05/2024 N/A
Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) PAR-22-147 06/08/2022 11/02/2024 U01
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) PAR-22-114 08/06/2022 01/24/2025 N/A
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) PAR-22-085 05/05/2022 05/08/2025 R01
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) PAR-22-086 05/16/2022 05/08/2025 R21
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) PAR-22-099 05/05/2022 05/08/2025 R01
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems –Basic Mechanisms of Health Effects  NOT-OD-22-022 12/09/2021 05/09/2023 N/A
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) PAR-22-061 01/05/2022 01/08/2025 R01
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) PAR-22-062 01/16/2022 01/08/2025 R21
Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology NOT-CA-22-003 11/30/2021 05/08/2023 N/A
The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional) PAR-21-348 11/15/2021 12/16/2023 U01
Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention NOT-CA-21-121 10/04/2021 09/08/2024 N/A
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) PAR-21-322 09/05/2021 09/08/2024 R01
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) PAR-21-323 09/16/2021 09/08/2024 R21
Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed) PAR-21-324 09/16/2021 09/08/2024 R03
Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards NOT-OD-20-055 03/05/2020 03/06/2023 N/A
Notice of Special Interest (NOSI): Developing Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) for Institutions with an emphasis on Down syndrome research (R15 Clinical Trial Not Allowed) NOT-OD-22-136 05/31/2022 04/11/2025 N/A
Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed) NOT-OD-21-092 06/28/2021 11/17/2023 R21
INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed) RFA-OD-21-007 10/03/2021 07/02/2024 R21
Development of Animal Models and Related Biological Materials for Down Syndrome Research (R24 Clinical Trials Not-Allowed) PAR-22-247 11/01/2022 05/26/2025 R24
Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project NOT-OD-22-123 05/26/2022 05/01/2025 R01
Notice of Special Interest (NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project NOT-OD-22-137 06/07/2022 06/02/2025 N/A
Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed) PAR-23-067 02/20/2023 01/08/2026  
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) PAR-21-138 06/07/2021 12/02/2024 N/A
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) PAR-21-331 10/12/2021 09/08/2024 R01
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) PAR-21-332 10/18/2021 09/08/2024 R21
Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia NOT-CA-21-057 05/06/2021 05/08/2023 N/A
Reminder: NIH Natural Disaster Policy – Wildfires NOT-OD-20-176 09/25/2020 N/A N/A
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) PA-21-071 11/16/2020 05/08/2023 N/A
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01) PAR-20-131 05/05/2020 05/08/2023 R01

Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)

PAR-23-051 01/17/2023 04/24/2025 U01

Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)

PAR-23-052

01/17/2023 10/24/2025 UH2
Email